US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

ホーム
投資
株式
オーストラリア
ASX
Connexion Mobility Ltd (CXZ) 銘柄情報

Connexion Mobility Ltd (CXZ)

0.024

0.00

(0.00%)

終了 6月6日 3:00PM

Connexion Mobility Ltd (CXZ) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

0.024

( - )

買値

0.023

売値

0.025

出来高

100,000

0.024 日の範囲 0.024

0.0215 52 週間の範囲 0.028

時価総額

前日終値

0.024

始値

0.024

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

AUD 1,677,829

発行済株式数

697,177,407

配当利回り

PER

5.58

1 株当たり利益 (EPS)

-

歳入

11.58M

純利益

2.53M

Connexion Mobility Ltd develops and commercializes fleet management software for the automotive industry in Australia, the United States, Canada, and Mexico. It offers OnTRAC and Connecion platforms, which are software as a service solutions that manage the courtesy transportation program to automot... Connexion Mobility Ltd develops and commercializes fleet management software for the automotive industry in Australia, the United States, Canada, and Mexico. It offers OnTRAC and Connecion platforms, which are software as a service solutions that manage the courtesy transportation program to automotive original equipment manufacturers and related mobility needs. The company was formerly known as Connexion Telematics Ltd and changed its name to Connexion Mobility Ltd in November 2023. Connexion Mobility Ltd is based in Melbourne, Australia. 詳細を表示

セクター

Technology

業界

Software & It Services

ウェブサイト

connexionmobility.com

本社

Melbourne, Australia

設立

-

Connexion Mobility Ltd is listed in the Technology sector of the オーストラリア証券取引所 with ticker CXZ. The last closing price for Connexion Mobility was AUD0.02. Over the last year, Connexion Mobility shares have traded in a share price range of AUD 0.0215 to AUD 0.028.

Connexion Mobility currently has 697,177,407 shares in issue. The market capitalisation of Connexion Mobility is AUD16.73 million. Connexion Mobility has a price to earnings ratio (PE ratio) of 5.58.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.001	-4	0.025	0.025	0.024	1136276	0.02487398	DE
4	-0.001	-4	0.025	0.025	0.0215	1171813	0.02302696	DE
12	-0.001	-4	0.025	0.028	0.0215	805159	0.0240582	DE
26	-0.002	-7.69230769231	0.026	0.028	0.0215	1773861	0.02536814	DE
52	-0.002	-7.69230769231	0.026	0.028	0.0215	1228199	0.02557913	DE
156	0.004	20	0.02	0.033	0.019	1157822	0.02583705	DE
260	0.008	50	0.016	0.033	0.008	1451954	0.02074362	DE

CXZ - Frequently Asked Questions (FAQ)

What is the current Connexion Mobility Ltd share price?

The current share price of Connexion Mobility Ltd is AUD 0.024

How many Connexion Mobility Ltd shares are in issue?

Connexion Mobility Ltd has 697,177,407 shares in issue

What is the market cap of Connexion Mobility Ltd?

The market capitalisation of Connexion Mobility Ltd is AUD 16.73M

What is the 1 year trading range for Connexion Mobility Ltd share price?

Connexion Mobility Ltd has traded in the range of AUD 0.0215 to AUD 0.028 during the past year

What is the PE ratio of Connexion Mobility Ltd?

The price to earnings ratio of Connexion Mobility Ltd is 5.58

What is the cash to sales ratio of Connexion Mobility Ltd?

The cash to sales ratio of Connexion Mobility Ltd is 1.03

What is the registered address of Connexion Mobility Ltd?

The registered address for Connexion Mobility Ltd is 162 Collins Street, Melbourne, Victoria, 3000

What is the Connexion Mobility Ltd website address?

The website address for Connexion Mobility Ltd is connexionmobility.com

Which industry sector does Connexion Mobility Ltd operate in?

Connexion Mobility Ltd operates in the Software & IT Services sector

US Market News

US Market News 2分前

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA BerobenatideJune 6, 2026 9:00 AM
Business Wire Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in

Investor082

Investor082 2分前

They are all a bunch of BS artists! They have trapped many naive retail families over the years by providing false hope and expectations.

Investor082

Investor082 4分前

See you in 2028 then! LP is likely to abandon Eden before that at some point than secure a commercial certification in 2028.

Keep a ton of dry powder. Looking forward to you bragging about averaging down in the coming weeks and months, LOL! ;)

Investor082

Investor082 7分前

In that case, forget about 2026 and 2027. Likely 2028 as well. C lab and Eden won’t certified for commercial production until 2028 at the earliest. Its more likely they will abandon Eden than secure commercial certification even in 2028. Have fun with the endless dilution in pennies! ;)

WhiteOwl

WhiteOwl 8分前

Am I missing something or does that Video say everything is experimental or just theory? I was under the impression they had perfected a workable unit? Just saying.

THE OLD OWL 🦉🦉🦉

hardlesson

hardlesson 11分前

You're one of the hardest working guys on ihub. Banging out the charts on a Saturday morning. Thanks always, and have a good weekend. :)

Investor082

Investor082 11分前

LP will be back there again in a couple years still pleading for a change (pathway act) so she can submit regulatory application to FDA in 2030, LOL!

Meanwhile outstanding shares ballooned to 5B+, LOL! ;)

WhiteOwl

WhiteOwl 12分前

Am I missing something or does that Video say everything is experimental or just theory? I was under the impression they had perfected a workable unit? Just saying.

THE OLD OWL 🦉🦉🦉

glenn1919

glenn1919 15分前

BCDA......BMGL.......BGMS......ACCL......CMND.........CGTL...........https://stockcharts.com/sc3/ui/?s=CMND&p=w&yr=1&mn=3&dy=0&id=p96837884856

Investor082

Investor082 16分前

No excuses when LP disappoints on this, OK?

I will check in on this message whenever there is a decision, LOL! ;)

WhenLambo

WhenLambo 16分前

FIFA is already on public record marketing them, what could be bigger than that? They’ll continue to put VuMe out there next week

train21

train21 17分前

DRIVEN IS BACK
so I guess we going to see 5 cents again ? well are we ?

Investor082

Investor082 19分前

Don't let LP and her toxic financiers screw you year after year, LOL! ;)

Instead invest in well known AI and tech stocks run by solid management crew.

glenn1919

glenn1919 20分前

STAK......SPHL.....SMTK......SAOR.....SNBR.......SCAG.....SPPL..................................https://stockcharts.com/sc3/ui/?s=SCAG&p=w&yr=1&mn=3&dy=0&id=p96837884856

jackinthegreen

jackinthegreen 20分前

Exactly - another round of press and hype can drive the price up a bit, but without substantial new contracts and revenue outside the consumer electronics space, it will only be a temporary bump. We’ve been here before - buying on the rumor is great, but what we need is actual profitability.

train21

train21 20分前

BOTH CEOs BLOCKED ME ON X
I MUST HAVE HIT THE NAIL ON THE HEAD
ANY CEO THAT BLOCKS QUESTIONS OF THEIR DECISIONS IS HIDING SOMETHING BIG AND BAD ???

rodman

rodman 21分前

There appears to be some life left in UEEC based upon the buying and pps increase this week.

cottonmather

cottonmather 21分前

Drey Dossier. The WH Ballroom ain't what it used to be. 17 minutes https://youtu.be/VbJ4ilDvGyc?si=DispyZYqLVQNJyms

USAFpatriot

USAFpatriot 21分前

Annual meeting 8k.

https://investorshub.advfn.com/stock-market/NASDAQ/novocure-NVCR/stock-news/98686681/form-8-k-current-report

train21

train21 22分前

$GTVH YOU ALL NEED TO FILE COMPLAINTS ON THE $OTC WEB SITE AND THE $FINRA WEB SITE
I CAN NOT JUST BE THE ONLY ONE FILING COMPLAINTS HERE ? SOME OF YOU GUYS LOST THOUSANDS $$$$$
CASEY IS A SHARE SELLING SCAMMMER AND MEDIA POSTING LIAR ......... AND THATS ALL THIS STOCK IS

HGiLS

Absolutely — let’s build the full, structured deep-dive you asked for. Below is everything:

• All Eliquis ANDA filers
• Their litigation outcomes
• Each filer’s non-infringement arguments
• Why none succeeded
• Drugs where generics did win using alternative

peafunke

peafunke 25分前

You told ‘who’ so? The fifa concerts are this coming week.

HGiLS

Yes — Eliquis (apixaban) has exactly the kind of ANDA litigation you’re asking about: cases where a generic filer challenged the Orange Book patents and argued non-infringement because their own formulation or manufacturing approach did not fall within the scope of the listed patents.

Teddytropics

Teddytropics 27分前

I will leave it up to you to decide..

I ask myself.. why is this guy so obsessed with Jason Black..?

That he wants to 'to tell on Jason Black' to all..

Where Jason Black isn't involved here anymore except for the CNNA OTC page still listing him..

Connexion Mobility

Pinnacle Minerals

Lamperd Less Lethal (ID)

Mont Royal Resources

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。